Sodium Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sodium Acetate: From Electrolyte Replacement to Congenital Prothrombin Deficiency
One-Sentence Summary
Sodium acetate is an electrolyte and alkalinizing agent that supplies sodium and acetate (metabolized to bicarbonate), and in Singapore it is used as an ingredient in intravenous fluids and dialysis solutions. The TxGNN model predicts it may be effective for congenital prothrombin deficiency, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model-only prediction, and no plausible mechanistic link has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records (no approved indication text is available) |
| Predicted New Indication | Congenital prothrombin deficiency |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sodium acetate is a source of sodium and acetate, and the acetate is metabolized in the body to bicarbonate. It is used as an electrolyte replenisher and alkalinizing agent in infusion and dialysis products.
Congenital prothrombin deficiency is a deficiency of coagulation factor II, and treatment requires replacement of the missing clotting factor. Sodium acetate has no known role in the coagulation cascade, and no plausible mechanistic link to this disease has been identified. The very high TxGNN score (0.9998) most likely reflects patterns in the knowledge graph rather than drug-specific biology, and it should not be read as evidence of efficacy.
Other top-ranked predictions are also unsupported. These include epiglottitis, urinary tract infection, sclerosing cholangitis, Ureaplasma and gonococcal urethritis, uterine inflammatory disease, and xanthogranulomatous pyelonephritis. They have no trials or supporting literature. For dyspepsia and gastroparesis, the retrieved publications are about gastric-emptying measurement, where ¹³C-sodium acetate serves as a diagnostic tracer rather than a treatment.
Singapore Market Information
Singapore has 20 valid single-ingredient registrations and no cancelled ones. The registration records do not include approved indication text. The main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06392P | Compound Sodium Lactate Intravenous Infusion BP | Injection | Not stated |
| SIN05592P | Lactated Ringer's Injection USP | Injection | Not stated |
| SIN06523P | Plasma-Lyte A Injection | Injection | Not stated |
| SIN13890P | Sterofundin ISO solution for infusion | Infusion, solution | Not stated |
| SIN11635P | Prismasol BO Solution | Solution | Not stated |
The remaining registrations include peritoneal dialysis solutions (Dianeal, Physioneal, Extraneal, Europersol), Lactoride 500 Infusion, and Gelaspan.
Safety Considerations
- Disease contraindications from the knowledge graph (not label text): These are drug-disease contraindication links, and they should be confirmed against the package insert.
- Kidney: kidney disease, chronic kidney disease, chronic renal failure, end-stage renal failure, anuria, nephrolithiasis, nephrocalcinosis, acute urate nephropathy
- Calcium and phosphorus: hypercalcemia, humoral hypercalcemia of malignancy, sarcoidosis, phosphorus metabolism disorders
- Heart: heart disease, cardiovascular disease, atrioventricular block, ventricular fibrillation, digitalis poisoning
- Potassium and muscle: hyperkalemic periodic paralysis, periodic paralysis, hypoaldosteronism, myotonia congenita
- Others: pyoureter, phenylketonuria and other phenylalanine metabolism disorders
- Drug Interactions: 30 interactions were found, and 20 are detailed in the data compiled for this report.
- Moderate: doxycycline, tetracycline, minocycline, acetylsalicylic acid, choline salicylate, ephedrine, pseudoephedrine, amphetamine, dextroamphetamine, benzphetamine, methenamine
- Minor: sulfonylureas (chlorpropamide, tolazamide, glipizide, glyburide, acetohexamide, tolbutamide), memantine, methotrexate
Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone (Evidence Level L5). There are no clinical trials or literature, and no plausible mechanistic link between sodium acetate and prothrombin deficiency. The other nine top predictions are likewise unsupported, and the literature for dyspepsia and gastroparesis reflects diagnostic tracer use, not treatment.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (the missing safety data currently blocks safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence linking sodium acetate to the predicted indication
- Approved indication text for the Singapore registrations, to confirm the original use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.